Cas:1062169-56-5 WYE-354 manufacturer & supplier

Chemical Name:WYE-354

CAS.NO:1062169-56-5

Synonyms:WYE354;pyrazolo pyrimidine,19;cc-506;S1266_Selleck;Methyl 4-[6-{4-[(methoxycarbonyl)amino]phenyl}-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate;1-Piperidinecarboxylic acid, 4-[6-[4-[(methoxycarbonyl)amino]phenyl]-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-, methyl ester;WYE-354

Molecular Formula:C₂₄H₂₉N₇O₅

Molecular Weight:495.531

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:594.2±50.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.692

PSA:123.94000

Exact Mass:495.223022

LogP:0.93

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like WYE354 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,WYE-354 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,cc-506 Use and application,S1266_Selleck technical grade,usp/ep/jp grade.

Related News: CROS NT built up its own biometric services portfolio: clinical data management, biostatistics, statistical programming and medical writing, through a series of acquisitions in the early 2010s. In 2013, CROS NT established a foothold in the U.S. with its purchase of Stat-Tech Services, which had a presence in the medical devices sector. CROS NT followed up the next year with its buy of biometrics services provider MDSL International to broaden its U.K. branch. WYE-354 manufacturer Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. WYE-354 supplier Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries. WYE-354 vendor ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. WYE-354 factory ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.